Divis Pharmaceuticals Private Limited
⚠️ Moderate Risk
FEI: 3005092623 • Hyderabad, Telangana • INDIA
FEI Number
3005092623
Location
Hyderabad, Telangana
Country
INDIAAddress
7 - 1 - 77 E 1 303 Divi Towers, , Hyderabad, Telangana, India
Moderate Risk
FDA Import Risk Assessment
This firm has a moderate history of FDA import refusals. Some attention may be warranted.
Statistics
Score Breakdown
How is this score calculated?
Proprietary Algorithm
- 40% Violation Severity — AI-assessed (1-10)
- 30% Refusal Volume — Logarithmic scale
- 20% Recency — Decays over 5 years
- 10% Frequency — Refusals per year
© ImportRefusal.com Original Analysis
Violation Summary
NOT LISTED
It appears the drug or device is not included in a list required by Section 510(j), or a notice or other information respecting it was not provided as required by section 510(j) or 510(k).
DIRECTIONS
The article is subject to refusal of admission pursuant to section 801(a)(3) in that it is a device whose label appears to not bear adequate directions for use.
INSANITARY
The article is subject to refusal of admission pursuant to section 801(a)(3) in that the article appears to have been prepared, packed, or held under insanitary conditions whereby it may have been contaminated with filth, or whereby it may have been rendered injurious to health.
UNAPPROVED
The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a new drug within the meaning of Section 201(p) without an approved New Drug Application (NDA).
Refusal History
| Date | Product | Violations | Division |
|---|---|---|---|
| 7/3/2017 | 60CCS09PHENYLEPHRINE HCL (ADRENERGIC) | 186INSANITARY | Division of Southeast Imports (DSEI) |
| 4/20/2015 | 62GAY50NAPROXEN SODIUM (ANTI-INFLAMMATORY) | Division of Northeast Imports (DNEI) | |
| 8/18/2006 | 60CCS09PHENYLEPHRINE HCL (ADRENERGIC) | New York District Office (NYK-DO) | |
| 6/6/2005 | 62GCZ50NAPROXEN SODIUM (ANTI-INFLAMMATORY) | New York District Office (NYK-DO) | |
| 7/15/2003 | 62UAS11DEXTROMETHORPHAN HYDROBROMIDE (ANTI-TUSSIVE/COLD) | New York District Office (NYK-DO) | |
| 3/18/2003 | 62UAS11DEXTROMETHORPHAN HYDROBROMIDE (ANTI-TUSSIVE/COLD) | New York District Office (NYK-DO) |
Frequently Asked Questions
What is Divis Pharmaceuticals Private Limited's FDA import refusal history?
Divis Pharmaceuticals Private Limited (FEI: 3005092623) has 6 FDA import refusal record(s) in our database, spanning from 3/18/2003 to 7/3/2017.
What is an FEI number?
FEI stands for Firm Establishment Identifier. It's a unique number assigned by the FDA to identify establishments that manufacture, process, pack, or hold food, drugs, medical devices, or other FDA-regulated products. Divis Pharmaceuticals Private Limited's FEI number is 3005092623.
What types of violations has Divis Pharmaceuticals Private Limited received?
Divis Pharmaceuticals Private Limited has been cited for 4 different violation type(s). Common FDA violations include adulteration (unsafe or unsanitary products), misbranding (incorrect or misleading labels), and regulatory non-compliance.
Where does this information about Divis Pharmaceuticals Private Limited come from?
All FDA import refusal data for Divis Pharmaceuticals Private Limited is sourced from the official FDA Data Dashboard (datadashboard.fda.gov), a public government database maintained by the U.S. Food and Drug Administration.
Data sourced from the FDA Data Dashboard, a public database maintained by the U.S. Food and Drug Administration.